Apyx Medical Expands Renuvion Launch into Chinese Market through Exclusive Partnership

Apyx Medical has launched its cosmetic technology, Renuvion, in China through an exclusive distribution agreement with GlamMoon Medical Technology. The launch follows initial market clearance from China's National Medical Products Administration and marks a significant step in Apyx's global expansion efforts. Analysts forecast an average target price of $4.00, indicating a potential upside of 57.48% from the current price of $2.54. The average brokerage recommendation is 2.7, indicating a "Hold" status.

Apyx Medical Corporation (NASDAQ: APYX) has made a significant stride in its global expansion strategy by launching its Renuvion technology in China. The launch follows initial market clearance from the National Medical Products Administration of China and is part of an exclusive distribution agreement with GlamMoon Medical Technology, a division of BeauCare Clinics Investment Co., Ltd. (BCC) [1].

Renuvion is a part of Apyx Medical's Helium Plasma Platform Technology products, which are marketed for the cosmetic surgery market. The technology offers surgeons a unique ability to provide controlled heat to tissue, supported by more than 90 clinical documents [1]. The launch in China marks a strategic move for Apyx Medical, which aims to tap into one of the world's largest and fastest-growing healthcare markets.

The distribution agreement with GlamMoon Medical Technology will facilitate the sales and marketing of Renuvion in China. GlamMoon operates over 60 medical aesthetics hospitals and clinics across 15 Chinese cities and manages a purchasing alliance with more than 400 members across 30+ cities [2]. The early response from physicians has been very positive, indicating strong potential for the technology in China [2].

Apyx Medical's President and CEO, Charlie Goodwin, stated, "The launch of Renuvion in China marks a significant milestone in our global expansion strategy. We are proud to bring our innovative technology to one of the world’s largest and fastest-growing healthcare markets." Ariel Liu, CEO of GlamMoon Medical Technology, echoed this sentiment, noting that "the early response from physicians has been very positive" [1].

The launch of Renuvion in China is expected to establish a commercial foundation for expanded regulatory approvals for the technology in the region. Analysts forecast an average target price of $4.00, indicating a potential upside of 57.48% from the current price of $2.54. The average brokerage recommendation is 2.7, indicating a "Hold" status [2].

In other recent news, Apyx Medical Corporation reported its first-quarter 2025 earnings, exceeding analyst expectations. The company achieved an earnings per share of -$0.10, outperforming the forecasted -$0.12. Revenue for the quarter reached $9.4 million, slightly above the projected $9.35 million [2].

References:
[1] https://www.nasdaq.com/press-release/apyx-medical-corporation-announces-launch-renuvionr-china-2025-07-28
[2] https://www.investing.com/news/company-news/apyx-medical-launches-renuvion-in-china-through-distribution-deal-93CH-4155147